Compare FLNG & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNG | DRTS |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | Bermuda | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2019 | 2021 |
| Metric | FLNG | DRTS |
|---|---|---|
| Price | $28.18 | $12.24 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $26.13 | $17.80 |
| AVG Volume (30 Days) | 321.5K | ★ 432.5K |
| Earning Date | 11-27-2026 | 11-19-2026 |
| Dividend Yield | ★ 10.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.04 | N/A |
| Revenue Next Year | N/A | $1,235.59 |
| P/E Ratio | $19.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.14 | $3.43 |
| 52 Week High | $33.40 | $15.79 |
| Indicator | FLNG | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 25.95 | 28.05 |
| Support Level | $25.74 | $11.24 |
| Resistance Level | $31.36 | $15.09 |
| Average True Range (ATR) | 0.79 | 0.54 |
| MACD | -0.31 | -0.27 |
| Stochastic Oscillator | 2.49 | 4.36 |
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The company's fleet consists of several LNG carriers on the water, and all of its vessels are of the latest generation equipped with two-stroke propulsion. Its fleet consists of M-type, Electronically Controlled, Gas Injection (MEGI) LNG carriers and Generation X Dual Fuel (X-DF) LNG carriers, offering improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. The company has one reportable segment: vessel operations, which generates revenue from the chartering of vessels to customers.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.